HOME > TOP STORIES

TOP STORIES

ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials

November 19, 2013
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29

November 19, 2013
BUSINESS Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery

November 18, 2013
BUSINESS Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business

November 15, 2013
REGULATORY Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices

November 14, 2013
BUSINESS Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon

November 14, 2013
BUSINESS Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%

November 13, 2013
BUSINESS GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President

November 12, 2013
BUSINESS 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End

November 11, 2013
BUSINESS Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura

November 8, 2013
REGULATORY “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary

November 7, 2013
REGULATORY Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs

November 7, 2013
BUSINESS Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes

November 6, 2013
ORGANIZATION Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads

November 5, 2013
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found

November 5, 2013
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study

November 1, 2013
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen

November 1, 2013
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium

October 31, 2013
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium

October 31, 2013
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo

October 30, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…